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Background: Advancements in genomic testing have led to the identification of single nucleotide polymorphisms
(SNPs) associated with prostate cancer. The clinical utility of SNP tests to evaluate prostate cancer risk is unclear.
Studies have not examined predictors of interest in novel genomic SNP tests for prostate cancer risk in a diverse
population.
Methods: Consecutive participants in the Fox Chase Prostate Cancer Risk Assessment Program (PRAP) (n = 40) and
unselected men from surgical urology clinics (n = 40) completed a one-time survey. Items examined interest
in genomic SNP testing for prostate cancer risk, knowledge, impact of unsolicited findings, and psychosocial
factors including health literacy.
Results: Knowledge of genomic SNP tests was low in both groups, but interest was higher among PRAP
men (p < 0.001). The prospect of receiving unsolicited results about ancestral genomic markers increased
interest in testing in both groups. Multivariable modeling identified several predictors of higher interest in a
genomic SNP test including higher perceived risk (p = 0.025), indicating zero reasons for not wanting testing
(vs ≥1 reason) (p = 0.013), and higher health literacy (p = 0.016).
Conclusions: Knowledge of genomic SNP testing was low in this sample, but higher among high-risk men.
High-risk status may increase interest in novel genomic tests, while low literacy may lessen interest.
Keywords: Genomic testing, Health literacy, Prostate cancer, Risk assessment, Single-nucleotide polymorphismBackground
In 2014, nearly 235,000 American men were diagnosed
with prostate cancer, making it the most common non-
cutaneous cancer diagnosis in this group [1]. While
many men will have their prostate cancer discovered at
an early stage and will be curable by a combination of
surgical and medical therapies, approximately 30,000
men will die from this disease [1]. African American
(AA) men have the highest race-specific risk for prostate
cancer, and AA race is associated with faster growth rate
and more aggressive disease [2,3]. Men with a family his-
tory of prostate cancer have a 2-to-7 fold increased risk
for the disease [4,5], with subsets at increased risk for
early-onset or aggressive disease [6,7]. Predicting risk for
prostate cancer development and particularly aggressive
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ease management. Advancements in genetic and gen-
omic testing technologies have led to the identification
of several single nucleotide polymorphisms (SNPs) with
association to prostate cancer [8]. These SNPs typically
are common in the population and contribute modestly
to increasing the risk for prostate cancer, in contrast to
mutations in germ-line cancer predisposition genes such
as BRCA2 or HOXB13 which have been shown to ex-
plain a fraction of prostate cancers related to a strong
inherited predisposition [9,10]. While the clinical utility
of SNP tests to evaluate prostate cancer risk is still un-
clear, the presence of these markers has been shown to
predict incremental increased risk for prostate cancer
above family history alone [11]. Thus there is potential
in the near future for growth of genomic SNP technol-
ogy in clinical prostate cancer risk stratification.
In recent years, the consistent association of race to
prostate cancer risk has lead researchers to investigateis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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to prostate cancer risk. It is hypothesized that genomic
markers of ancestry may add additional information in
the estimation of prostate cancer risk above and beyond
other genetic and/or clinical risk markers like prostate
specific antigen (PSA) level [12,13]. Indeed, many gen-
etic association studies are designed to factor in genetic
ancestry to assess the strength of association of candi-
date variants with prostate cancer risk [14]. Ancestral
markers themselves may in fact inform risk for prostate
cancer independent of other risk factors [15]. Knowledge
of the association of genetic ancestry to disease risk (like
cancer risk) is evolving [14,15], and may play a meaning-
ful role in risk assessment and risk management of dis-
eases in the future.
Despite advancements in genomic testing, however, it
is unclear how genetic testing technologies will, in the
short-term, affect testing procedures like the process of
informed consent, as well as patient interest and uptake
of these tests. Sanger sequencing of single- or oligo-gene
sites is being rapidly replaced by faster next-generation
sequencing (NGS) technologies with the ability to se-
quence thousands of genetic loci in a single test. Clinical
standards for obtaining informed consent and for dis-
closure of results are actively under development, but re-
main complicated due to the potential high volume of
information produced by a single test and the uncertain
clinical importance of many findings (e.g. variants of un-
certain clinical significance). Studies conducted before
the advent of large-scale NGS-based genomic testing
have reported largely positive attitudes and high interest
in genetics and genetic testing in the general public and
among men at risk of prostate cancer [16]. Predictors of
interest in genetic testing to stratify prostate cancer risk
have included more positive attitudes toward genetic
testing, better understanding and higher knowledge of
genetics, stronger personal and/or family history of pros-
tate cancer, and higher perceived risk of prostate cancer
[16-18]. Nonetheless, few studies have not previously ex-
amined patients’ awareness of genomic SNP tests for
prostate cancer risk or their interest in a genomic test if
it were considered standard-of-care as part of the evalu-
ation of prostate cancer risk. Further, other implications
of genomic testing in addition to those already men-
tioned, including the potential for generation of ancillary
or unsolicited information about genetic ancestry during
testing, has also not been well studied.
In the current study, we sought to broadly explore fac-
tors associated with awareness and interest in genomic
testing for prostate cancer risk in men recruited from
two outpatient clinics in a tertiary cancer center setting.
One group included unaffected men with racially and
demographically diverse backgrounds being screened in
the Prostate Cancer Risk Assessment Program, and theother included men seen in a surgical urology clinic with
varied personal and family histories of prostate cancer.
To better understand how psychological factors known
to be important in medical decisions and specifically
genetic testing decisions affect interest in genomic SNP
testing within this diverse population, we also included
attitudinal measures and measures of perceived cancer
risk adapted from previous research, as well as measures
of health literacy and numeracy in our analyses [19,20].
Based on the previous literature, we hypothesized that
perceived risk of prostate cancer, knowledge of genetics
and genomic SNP tests, positive attitudes towards gen-
omic SNP testing, and higher health literacy/numeracy
skill would positively impact interest in genomic testing.
Since prior literature has reported mixed results regard-
ing interest in genetic testing and reaction to race-based
medicine in African Americans [8,21-26], we expected
that the generation of unsolicited information about ra-
cial ancestry from a genomic test would overall nega-
tively impact interest in testing, especially in our sample
enriched in African American men.
Materials and methods
Recruitment
Participants were patients at Fox Chase Cancer Center
and were recruited consecutively from outpatient clinics
(December 2012-February 2013). Recruitment targeted
two groups—1) unaffected participants undergoing pros-
tate cancer screening in the Prostate Cancer Risk
Assessment Program (PRAP) in annual follow-up, and
2) men seen in a surgical urology clinic, without exclu-
sion for personal history or risk of prostate cancer. Men
were introduced to the study by their provider, and pa-
tients were initially recruited consecutively at the end of
their office visit. Recruitment of AA men was then ex-
tended in both groups to increase racial diversity until
the goal of 40 subjects per group (n = 80 total) was
achieved.
Patient samples
The FCCC Prostate Cancer Risk Assessment Program
(PRAP) is a screening and research program for men at
high-risk for prostate cancer [27]. Eligibility criteria in-
clude men ages 35–69 with one first-degree relative with
prostate cancer or two second-degree relatives with
prostate cancer (same side of the family), or any AA
man regardless of family history of prostate cancer, or
BRCA mutation carrier. AA men comprise 60% of the
PRAP cohort, and 60% of the entire cohort reports a
family history of prostate cancer [27]. A second sample
of unselected male patients was consecutively recruited
from three outpatient general urology clinics (referred to
as URO hereafter). These two populations were chosen
to provide a broad sample of men who may have
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test for hereditary prostate cancer risk, including men
without prostate cancer at increased risk of prostate can-
cer (PRAP patients) having a yearly evaluation in a high
risk clinic, and unselected men seeing their urologist for
a follow-up appointment unrelated to prostate cancer
risk assessment, such as evaluation for a non-oncologic
issue (e.g. urinary retention) or an oncologic issue (e.g.
bladder cancer).
Survey
The survey was administered in person by study personnel
and took approximately 10 minutes to complete. Before
beginning the survey questions, participants were briefly
introduced to the concept of genomic SNP testing for
prostate cancer risk with the following information “The
following question will help us understand your awareness
of single nucleotide polymorphisms (SNPs) and SNP tests.
As you may already know, new blood tests that measure
SNPs (pronounced SNIPS) are available over the Internet
to help identify men at increased risk of prostate cancer. A
SNP (single-nucleotide polymorphisms) is a marker of pos-
sible increased cancer risk present in your genes, but it
does not directly cause cancer.”
Outcome items Two face-valid items scored on a 5-
point Likert scale were used to assess participants’
awareness of genomic SNP tests to gauge prostate can-
cer risk: “Before today, how aware were you of SNP tests
used to help patients understand their risk of prostate
cancer?” and “Were you aware that SNP tests for
prostate cancer risk are available to the public over the
Internet?” Two additional items assessed interest in gen-
omic SNP testing for prostate cancer risk. The first
assessed interest in a test that was considered standard-
of-care:“I would be interested in having a SNP test if it
was a standard part of the evaluation of risk for prostate
cancer (test IS standard of care).” The second gauged
interest if testing also revealed unsolicited information
about ancestry “How would your interest in having a
SNP test for prostate cancer risk change if the test
ALSO revealed information on your ancestral or genetic
origin, such as the amount or percent of your DNA that
is Asian, African, or European in origin?”
Demographic characteristics and prostate cancer
history Age, self-identified race, marital status, and edu-
cational attainment were collected. Personal history of
prostate cancer and number of first-degree relatives
(FDRs) with prostate cancer was also queried.
Perceived risk of prostate cancer Participants gauged
their risk of developing prostate cancer relative to a manof average risk using a 5-point Likert scale (“Much lower,
a little lower, same, a little higher, much higher.”
Attitudes towards genomic SNP testing Reasons for
wanting (n = 7 items) or not wanting (n = 7 items) a gen-
omic SNP test for prostate cancer risk were adapted
from items assessing benefits and barriers to genetic
testing [28].
Health literacy Three validated items [29] screened for
low health literacy. Numeracy was assessed by a vali-
dated 3-item measure [30].
Statistical analyses Summary statistics were examined
for differences in demographic characteristics and out-
comes by study group (PRAP high risk men or Urology
clinic men) using chi-square tests, as we hypothesized
that awareness and interest in genomic SNP testing
could differ based on whether men participate in a high-
risk surveillance program versus not [31,32]. Univariate
associations of demographic and psychological measures
of strong interest in genomic SNP testing were tested by
chi-square tests. In multivariable modeling, we devel-
oped a model including study group and psychological
predictors that were associated (p < 0.10) with strong
interest in SNP testing. In a second model, to reduce
collinearity we omitted study group as a covariate so
that we could examine other predictors which differed
by study group (race, age, personal history and family
history). Covariates were included in a multivariable lo-
gistic regression model, with strong interest in genomic
SNP testing for prostate cancer risk (Yes/No) as the out-
come. Coefficients are reported as odds ratios with 95%
confidence intervals and p-values. A significance level
with a two-sided α = 0.05 was used to assess the multi-
variable analyses.
The study was approved by the Fox Chase Cancer
Center Institutional Review Board. All participants pro-
vided signed informed consent.
Results
Eighty men, 40 from the PRAP sample (PRAP) and 40
from the unselected general urology sample (URO),
completed the survey. Participant characteristics are
summarized in Table 1. Participants were 40–84 years of
age (mean 61.9) with PRAP group being younger than
URO group (mean age 59.0 vs 64.7 years, p = 0.004). The
majority of participants reported White race (66%) and
were married (81%). Educational attainment was
diverse–50% had a college degree but 31% had a high
school diploma or less. Over half 54% (43/80) had a fam-
ily history of prostate cancer, with 28% reporting one
FDR and 26% at least two FDRs with prostate cancer.
URO group was more than twice as likely to report a
Table 1 Participant characteristics
Characteristic All PRAP group Urology group p
N (%) N (%) N (%)
Age 0.014
40-49 7 (8.8) 6 (15.0) 1 (2.5)
50-59 20 (25.0) 14 (25.0) 6 (15.0)
60-69 39 (48.8) 16 (40.0) 23 (57.5)
70-84 14 (17.5) 4 (10.0) 10 (25.0)
Race 0.033
African American 27 (33.8) 18 (45.0) 9 (22.5)
White 53 (66.3) 22 (55.0) 31 (77.5)
Marital Status 0.42
Single 9 (11.3) 4 (10.0) 5 (12.5)
Married 65 (81.3) 31 (77.5) 34 (85.0)
Divorced 4 (5.0) 3 (7.5) 1 (2.5)
Widowed 2 (2.5) 2 (5.0) 0 (0.0)
Education 0.69
Some HS 3 (3.8) 1 (2.5) 2 (5.0)
High School (HS) 22 (27.5) 12 (30.0) 10 (25.0)
Some college 15 (18.8) 9 (22.5) 6 (15.0)
College degree 40 (50.0) 18 (45.0) 22 (55.0)
Internet access (yes) 77 (96.3) 37 (92.5) 40 (100) 0.24
Prostate cancer history
Personal history <0.001




None 37 (46.3) 12 (30.0) 25 (62.5)
1 22 (27.5) 13 (32.5) 9 (22.5)
2+ 21 (26.3) 15 (37.5) 6 (15.5)
Bold: Results significant (p < 0.05).
Table 2 Awareness and interest in genomic SNP testing
for prostate cancer risk
Item PRAP group Urology group p
N (%) N (%)
Awareness
Awareness of genomic SNP
testing for PC risk
0.38
Not aware 28 (70.0) 34 (85.0)
A little 4 (10.0) 1 (2.5)
Somewhat 4 (10.0) 3 (7.5)
Quite 2 (5.0) 2 (5.0)
Very aware 2 (5.0) 0 (0.0)
Awareness of genomic SNP
tests on the Internet
Not aware 40 (100.0) 38 (95.0) 0.49
Missing 0 (0.0) 2 (5.0)
Interest
Interest in genomic SNP
testing if standard-of-care
<0.001
Strongly disagree 0 (0.0) 6 (15.0)
Sort of disagree 0 (0.0) 6 (15.0)
Neither agree nor disagree 0 (0.0) 4 (10.0)
Sort of agree 10 (25.0) 10 (25.0)
Strongly agree 30 (75.0) 14 (35.0)
Interest change if ancestry
markers revealed
0.58
No change 20 (50.0) 17 (42.5)
Maybe more interest 12 (30.0) 17 (42.5)
Definitely more interest 8 (20.0) 6 (15.0)
Bold: Results significant (p < 0.05).
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majority (62%) of the men in the URO group had a per-
sonal history of prostate cancer. PRAP recruits men at
increased risk of prostate cancer—therefore, none of the
40 PRAP participants had a personal history of prostate
cancer.
The majority of men were unaware of the current
availability of genomic SNP testing for prostate cancer
risk (78%) [PRAP (70%) and URO (85%)(p = 0.38)]
(Table 2) Surprisingly, though nearly all of the men had
access to the Internet at home (96%), none of the men
was aware that genomic SNP testing for prostate cancer
risk was available over the Internet. However, PRAP
men were more likely to agree to the statement, “I would
be interested in having a SNP test if it was a standard
part of the evaluation of risk for prostate cancer (test ISstandard of care).” (PRAP: 75% “strongly agree”; fewer
men in the URO group agreed, and 30% disagreed (30%
“sort of” or “strongly” disagreed) (p < 0.001).
Refuting our hypothesis, more than half (53%) of par-
ticipants expressed increased interest in genomic SNP
testing when informed that the test would also reveal
unsolicited information about ancestry. For PRAP men,
50% either expressed “maybe” or “definitely” more inter-
est in genomic testing where ancestral markers of race
would also be reported. Among the URO group, 58%
of men expressed “maybe” or “definitely” more interest
(p = 0.58). However, in the URO group, the change in
interest with ancestry information was more pronounced
among men with a personal history of prostate cancer
versus those without (24% vs 0% expressing “definitely
more interest”,p = 0.07).
Attitudes toward SNP testing
When asked to select reasons for getting SNP testing, 64
men (80%) of the combined groups indicated “I just
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cated “So I could plan for the future” and also for “To
learn if my children are at risk”. Men were also asked
about reasons for not getting SNP testing. Twelve men
(15%) of the group indicated “I can’t do anything to pre-
vent it”, while other reasons for not having SNP testing
were indicated by only 4%-10% of the men (Table 3).
Univariate analyses
URO men were less likely than PRAP men to have
strong interest in SNP testing for prostate cancer risk
(OR 0.18, 95% CI 0.07-0.470). Univariate associations be-
tween predictors and strong interest in genomic SNP
testing are found in Table 4. The number of FDRs
with prostate cancer was the only demographic or
family history characteristic predictive of strong inter-
est (p = 0.008). Interest was also associated with higher
perceived risk of prostate cancer (p = 0.039) and rea-
sons for wanting genomic SNP testing (p = 0.001),
while men who indicated at least one reason for not
wanting genomic SNP testing were less interested in
testing (p = 0.003), as were men who had a personal
history of prostate cancer (p = 0.001). Reporting need-
ing help reading medical materials was associated with
lower interest in testing (p = 0.007).
Multivariable model
Multivariable models were developed to examine the
relative impact of demographic, family and personal his-
tory, and psychosocial predictors of interest in having a
genomic SNP test for prostate cancer risk. The first
model included study group with psychological variablesTable 3 Reasons for wanting and not wanting SNP testing
n (percent)
Reasons for wanting SNP testing
So I could plan for the future. 47 (58.8)
So I could make a decision about getting more
health insurance.
15 (18.8)
To learn if my children are at risk. 47 (58.8)
I suspect that I am a gene carrier for cancer. 38 (47.5)
I just want to know. 64 (80.0)
To be able to take better care of myself. 40 (50.0)
To know if I need to have screening tests more often. 44 (55.0)
Reasons for not wanting SNP testing
I am concerned about my emotional reaction. 3 (3.8)
I am concerned about my partner’s reaction. 4 (5.0)
I am concerned about my family’s reactions. 4 (5.0)
I just don’t want to know. 8 (10.0)
I can’t do anything to prevent it. 12 (15.0)
I would worry about how it would affect my insurance. 4 (5.0)that were significantly associated in the univariate ana-
lyses. In this model, study group remained a statistically
significant predictor: URO men vs PRAP men, adjusted
OR = 0.18 (95%CI 0.06-0.61) (Table 5). To avoid collin-
earity issues, we developed a second model which omit-
ted study group and instead included age, race and
personal and family history of cancer as covariates,
which had been shown to differ by study group (Table 1).
Results from this second model are presented in Table 6.
While the small sample sizes limit interpretability of the
model, the results suggest that strong family history
of cancer (p = 0.026) and higher perceived risk of cancer
(p = 0.036) are all positively associated with strong
interest in having a genomic SNP test, while negative
attitudes towards genetic testing (≥1 reason marked
for not wanting genomic SNP testing)(p = 0.020),
lower health literacy (needing help reading medical
materials)(p = 0.017), and personal history of prostate
cancer (p = 0.042) were negatively associated with interest
in genomic SNP testing.
Discussion
Research in recent years has identified several genetic
variants with strong statistical associations to prostate
cancer risk [8]. The magnitude of risk associated with
these SNPs is relatively modest with limited discrimina-
tive ability for cancer, leading to uncertainty regarding
the clinical utility of these markers [33,34]. However,
these markers represent a fraction of the knowledge of
genetic contribution to prostate cancer risk, and as more
genetic determinants are uncovered there is greater like-
lihood of a potential clinical role in prostate cancer risk
assessment. Patient interest in genomic testing will be
expected to play a critical role in the near future as the
clinical utility of genomic risk testing is determined. This
study was performed to examine correlates of interest in
genomic SNP testing in a population diverse by race,
prostate cancer personal history and family history, in an
effort to broadly describe factors that may be important
for further investigation.
We found that there was high interest in genomic
SNP testing but low awareness of the test. The strongest
predictors of interest in genomic SNP testing included:
being at increased risk of prostate cancer due to family
history and/or AA race (PRAP), having a stronger family
history of cancer, or having a higher perceived risk of
cancer. Our findings complement prior studies that have
reported a correlation between perceived risk, family his-
tory, and prostate cancer screening [35,36]. However, it
must be appreciated that the relationship between atti-
tudes towards genetics, interest in testing, and actual up-
take in testing is complex. Generally, the public and
high-risk patients report positive attitudes towards the
anticipated benefits of genetic testing and report high
Table 4 Univariate associations of demographic and
psychological measures with strong interest in genomic
SNP testing




PRAP 40 30 (75.0)
Urology, 40 147 (35.0)
Demographic
Age 0.10
40-64 48 30 (62.5)
65+ 32 14 (43.8)
Race 0.59
African American 27 16 (59.3)
White 53 28 (52.8)
Marital Status 0.32
Married 65 34 (52.3)
Other 15 10 (66.7)
Education 0.54
High school or less 25 16 (64.0)
Some college 15 8 (53.3)
College or more 40 20 (50.0)
Internet access 0.25
Yes 77 41 (53.2)
No 3 3 (100.0)
FDRs with prostate cancer 0.008
0 37 18 (48.6)
1 22 8 (36.4)
2+ 21 18 (85.7)
Personal history of prostate cancer 0.001
No 55 37 (67.3)
Yes 25 7 (28.0)
Psychological measures
Perceived risk of prostate
cancer
0.039
Lower 11 3 (27.3)
Same 22 12 (54.5)
A little higher 24 11 (45.8)




0-3 reasons marked 35 12 (34.3)
4-7 reasons marked 45 32 (71.1)
Reasons for not wanting
SNP testing
0.003
None checked 60 39 (65.0)
At least 1 checked 20 5 (25.0)
Table 4 Univariate associations of demographic and
psychological measures with strong interest in genomic
SNP testing (Continued)
Health literacy
Help reading materials 0.007
“None of the time” 27 9 (33.3)
Not “none of the time” 53 35 (66.0)
Confidence in filling out forms 0.78
“Extremely confident” 59 33 (55.9)




“None of the time” 12 5 (41.7)
Not “none of the time” 67 38 (56.7)
Numeracy skill 0.22
Low numeracy (0 or 1 item correct) 16 11 (68.8)
High numeracy (2 or 3 items correct) 64 33 (51.6)
Knowledge score
General genetics knowledge items 0.21
1-4 correct 10 4 (40.0)
5-6 42 27 (64.3)
7-8 28 13 (46.4)
Genomic SNP test knowledge items 0.65
0 correct 37 19 (51.4)
1-3 26 14 (53.8)
4-6 17 11 (64.7)
Bold: Results significant (p < 0.05).
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(e.g. education, worry, and perceived risk) and character-
istics of the test and its results may also negatively
modulate interest independent of positive attitudes
[37-42].Whether interest in SNP testing will be associ-
ated with uptake of testing is unknown. Of important
note was the low awareness of the availability of SNP
testing on the Internet in this select group of patients re-
ceiving care at a tertiary care cancer center, many with a
personal or familial risk of prostate cancer. This may be
seen as surprising particularly given the steep rise in
direct-to-consumer marketing of personal genome test-
ing [43]. The reasons for this low awareness of Internet
based genome testing in our study are unclear, but will
need to be explored in follow-up studies.
Interestingly, we found that a higher knowledge score
for items related to genetics and genomics did not im-
pact men’s preferences for genomic SNP testing, either
by increasing or decreasing interest. However checking
even one reason for not wanting SNP testing was signifi-
cantly associated with lower interest in testing. Though
our sample is small, this finding suggests that interest in
Table 5 Multivariable model examining clinic group and
psychological predictors of strong interest in a genomic
SNP test for prostate cancer risk






Perceived risk of prostate cancer 0.025
Lower 0.17 0.02-1.25
Same referent
A little higher 0.25 0.06-1.15
Much higher 2.47 0.49-12.34




At least 1 checked 0.11 0.03-0.50
Health Literacy 0.057
Help reading medical materials
“None of the time” referent
Not “none of the time” 0.30 0.09-1.04
Bold: Results significant (p < 0.05).
Note: Reasons for wanting SNP testing omitted from the model due to
collinearity issues.
Table 6 Multivariable model examining demographic,
personal and family history, and psychological predictors
of strong interest in a genomic SNP test for prostate
cancer risk
Predictor OR 95% confidence
interval
P







African American 0.97 0.17-5.62 0.97
White referent
FDRs with prostate cancer
0 referent 0.022
1 0.42 0.08-2.28
2 or more 17.06 1.38-211.5
Perceived risk of prostate cancer 0.026
Lower 0.07 0.01-0.89
Same referent
A little higher 0.11 0.01-0.87
Much higher 2.11 0.25-17.65
Reasons for wanting SNP testing 0.54
0-3 reasons checked referent
4-7 reasons checked 1.77 0.29-10.85




At least 1 checked 0.10 0.02-0.62
Health Literacy 0.017
Help reading medical materials
“None of the time” referent
Not “none of the time” 0.12 0.02-0.69
Bold: Results significant (p < 0.05).
Hall et al. Hereditary Cancer in Clinical Practice  (2015) 13:11 Page 7 of 9and uptake of a novel form of genomic testing may be
reduced by specific negative views of testing. Generally
positive attitudes and/or high knowledge of the role of
genetics and genomics in medicine may be less influen-
tial in decisions. We also found evidence that health lit-
eracy may impact interest in testing independent of
knowledge and numeracy skill. Previous research has
shown health literacy to be predictive of health behav-
iors such as cancer screening [44] and genetic informa-
tion comprehension [45], and our findings are consistent
with this literature.
Our study is among the first to examine high-risk pa-
tients’ preferences toward management of unsolicited or
secondary information about ancestry from genomic
testing, and thus provides important preliminary insight
into the potential impact commercial large-scale gen-
omic testing could have in this population. [19] To our
surprise, unlike prior research demonstrating patient dis-
pleasure with race-based personalized medicine [22,45],
our study supported a “two-for-one” concept of the posi-
tive perception of receiving additional genetic ancestry
information along with genomic risk for prostate cancer.
More than half of all participants expressed increased
interest in genomic SNP testing if ancestry information
was included and revealed, relative to interest in gen-
omic testing in the absence of unsolicited information,
while no participants reported a decline in interest(46% reported no change in interest). Research continues
to explore the evolving spectrum of genetic and genomic
information use and management in patients and the
general public [22,46,47]. Studies have found the general
public to be interested in gaining and/or having control
over receipt of secondary information discovered during
focused genetic testing, in the pharmacogenetic setting
or hereditary risk setting [48]. Nonetheless, studies to
better understand how cancer patients and others weigh
decisions to receive this information, particularly in light
of personal disease burden and other factors, remain to
be performed, but early research in this area has begun
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tion that drive patient decisions including information
(i.e. disease) risk, severity, and treatability [42,49]. In-
deed some ancillary genetic information, like ancestral
markers, may be more easily accepted by patients than
information like increased risk of cancer because they
would not be used to target treatments in a race-based
approach [22,47] and would not be associated with po-
tentially burdensome information and the need for
health behavior modifications which has been shown to
be a deterrent to genetic testing [42].Equally, guidelines
for best practices for consenting patients for testing
that may uncover unsolicited information and for
returning findings to them are still under development
but hotly debated in light of the recent opinion state-
ment published by the ACMG [50], among other
reasons.
There are several limitations to note when interpreting
this study. Most importantly, we assessed interest in and
attitudes toward genomic SNP testing in a hypothetical
format—therefore opinions may not fully reflect testing
intentions and/or behaviors in a real world setting. How-
ever, men at high risk of prostate cancer or with a previ-
ous diagnosis of prostate cancer, and men who seek
expert care in a high risk prostate risk clinic and/or
through a tertiary care cancer center are unquestionably
a relevant population who would have access to this type
of testing. Secondly, the small size of our sample may
have limited our ability to detect weaker associations be-
tween our outcomes and independent variables, and
may have limited our ability to adequately control for
the effects of the multiple independent variables in-
cluded in our regression models. Future studies with lar-
ger samples of participants will be important to further
investigate the independent effects of demographic and
psychosocial factors on interest in and uptake of gen-
omic testing. Finally, our finding of increased interest in
genomic testing that is accompanied by unsolicited find-
ings related to ancestral origins, while consistent with
other studies, may not reflect how participants would
react to unsolicited information of a different nature
produced by a genomic SNP test. For example, men may
express less interest in a test that revealed risk of
prostate cancer in themselves but also that revealed a
risk of early-onset breast cancer in their daughters,
or, alternatively, a risk of early-onset dementia in
family members.
In conclusion, limited health literacy and negative atti-
tudes towards genetics may significantly dampen interest
in testing. Nonetheless, patients may view unsolicited
genetic information from testing in a positive light. At
the present time, such insights into testing awareness of
available SNP testing and interest in such testing do not
automatically imply that clinicians should recommendthe current SNP tests on prostate cancer risk as being
clinically meaningful to our patients and to the general
public. The clinical utility of SNP tests is currently un-
clear. Studies investigating the relationship of interest in
genomic testing to action, and the psychosocial impact
of unsolicited genomic information on patients in the
real world setting will be valuable in the near future.
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